Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has been assigned an average recommendation of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $24.64.

A number of analysts recently commented on the company. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Wednesday, July 10th. TheStreet upgraded Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Wednesday, August 7th. Wells Fargo & Co set a $29.00 target price on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 6th. Finally, BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $20.78, for a total value of $207,800.00. Following the sale, the director now directly owns 49,309 shares in the company, valued at $1,024,641.02. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jason B. Shandell sold 6,615 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $20.31, for a total value of $134,350.65. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,557 shares of company stock worth $549,583. Corporate insiders own 30.80% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the business. Financial Gravity Wealth Inc. bought a new stake in shares of Amphastar Pharmaceuticals during the 1st quarter valued at $43,000. Quadrant Capital Group LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 1st quarter valued at $53,000. Acadian Asset Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at $88,000. Bank of Montreal Can raised its stake in shares of Amphastar Pharmaceuticals by 130.7% during the 2nd quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock valued at $104,000 after purchasing an additional 2,789 shares during the period. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Amphastar Pharmaceuticals by 52,407.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,351 shares of the company’s stock valued at $150,000 after purchasing an additional 7,337 shares during the period. Hedge funds and other institutional investors own 48.12% of the company’s stock.

Amphastar Pharmaceuticals stock traded up $0.08 during mid-day trading on Friday, reaching $22.27. 526 shares of the company’s stock were exchanged, compared to its average volume of 191,264. The business’s fifty day simple moving average is $20.31 and its 200 day simple moving average is $21.31. The firm has a market capitalization of $1.01 billion, a PE ratio of 105.76 and a beta of 1.35. Amphastar Pharmaceuticals has a one year low of $17.71 and a one year high of $25.43. The company has a quick ratio of 1.83, a current ratio of 2.81 and a debt-to-equity ratio of 0.13.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.05. The business had revenue of $79.00 million for the quarter, compared to analyst estimates of $78.90 million. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. Amphastar Pharmaceuticals’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period last year, the company posted $0.03 earnings per share. On average, sell-side analysts forecast that Amphastar Pharmaceuticals will post 0.15 earnings per share for the current year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Further Reading: How interest rates affect municipal bond prices

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.